Pharmacokinetics of pergolide after intravenous administration to horses

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To determine the pharmacokinetics of pergolide after IV administration to horses. Animals: 8 healthy adult horses. Procedures: Pergolide mesylate was administered IV at a dose of 20 µg/kg (equivalent to 15.2 µg of pergolide/kg) to each horse, and blood samples were collected over 48 hours. Pergolide concentrations in plasma were determined by means of high-performance liquid chromatography'tandem mass spectrometry, and pharmacokinetic parameters were determined on the basis of noncompartmental methods. Results: After IV administration of pergolide, mean ± SD clearance, elimination halflife, and initial volume of distribution were 959 ± 492 mL/h/kg, 5.64 ± 2.36 hours, and 0.79 ± 0.32 L/kg, respectively. Conclusions and clinical relevance: With an elimination half-life of approximately 6 hours, twice-daily dosing may be more appropriate than once-daily dosing to reduce peak-trough fluctuation in pergolide concentrations. Further pharmacodynamic and pharmacokinetic studies of pergolide and its metabolites will be necessary to determine plasma concentrations that correlate with clinical effectiveness to determine the therapeutic range for the treatment of pituitary pars intermedia dysfunction.
Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalAmerican Journal of Veterinary Research
Volume76
Issue number2
DOIs
Publication statusPublished - Feb 2015

Fingerprint

Pergolide
intravenous injection
Intravenous Administration
pharmacokinetics
Horses
Pharmacokinetics
horses
half life
pharmacology
high performance liquid chromatography
Half-Life
metabolites
Intermediate Pituitary Gland
therapeutics
blood
dosage
Tandem Mass Spectrometry
animals
sampling
High Pressure Liquid Chromatography

Cite this

@article{941a173a973c4dc68e4abcbfe8ebdf2e,
title = "Pharmacokinetics of pergolide after intravenous administration to horses",
abstract = "Objective: To determine the pharmacokinetics of pergolide after IV administration to horses. Animals: 8 healthy adult horses. Procedures: Pergolide mesylate was administered IV at a dose of 20 {\^A}µg/kg (equivalent to 15.2 {\^A}µg of pergolide/kg) to each horse, and blood samples were collected over 48 hours. Pergolide concentrations in plasma were determined by means of high-performance liquid chromatography'tandem mass spectrometry, and pharmacokinetic parameters were determined on the basis of noncompartmental methods. Results: After IV administration of pergolide, mean ± SD clearance, elimination halflife, and initial volume of distribution were 959 ± 492 mL/h/kg, 5.64 ± 2.36 hours, and 0.79 ± 0.32 L/kg, respectively. Conclusions and clinical relevance: With an elimination half-life of approximately 6 hours, twice-daily dosing may be more appropriate than once-daily dosing to reduce peak-trough fluctuation in pergolide concentrations. Further pharmacodynamic and pharmacokinetic studies of pergolide and its metabolites will be necessary to determine plasma concentrations that correlate with clinical effectiveness to determine the therapeutic range for the treatment of pituitary pars intermedia dysfunction.",
keywords = "Corticotropin, Pergolide",
author = "David Rendle and Kristopher Hughes and Gregory Doran and Scott Edwards",
note = "Includes bibliographical references.",
year = "2015",
month = "2",
doi = "10.2460/ajvr.76.2.155",
language = "English",
volume = "76",
pages = "155--160",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "2",

}

Pharmacokinetics of pergolide after intravenous administration to horses. / Rendle, David; Hughes, Kristopher; Doran, Gregory; Edwards, Scott.

In: American Journal of Veterinary Research, Vol. 76, No. 2, 02.2015, p. 155-160.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetics of pergolide after intravenous administration to horses

AU - Rendle, David

AU - Hughes, Kristopher

AU - Doran, Gregory

AU - Edwards, Scott

N1 - Includes bibliographical references.

PY - 2015/2

Y1 - 2015/2

N2 - Objective: To determine the pharmacokinetics of pergolide after IV administration to horses. Animals: 8 healthy adult horses. Procedures: Pergolide mesylate was administered IV at a dose of 20 µg/kg (equivalent to 15.2 µg of pergolide/kg) to each horse, and blood samples were collected over 48 hours. Pergolide concentrations in plasma were determined by means of high-performance liquid chromatography'tandem mass spectrometry, and pharmacokinetic parameters were determined on the basis of noncompartmental methods. Results: After IV administration of pergolide, mean ± SD clearance, elimination halflife, and initial volume of distribution were 959 ± 492 mL/h/kg, 5.64 ± 2.36 hours, and 0.79 ± 0.32 L/kg, respectively. Conclusions and clinical relevance: With an elimination half-life of approximately 6 hours, twice-daily dosing may be more appropriate than once-daily dosing to reduce peak-trough fluctuation in pergolide concentrations. Further pharmacodynamic and pharmacokinetic studies of pergolide and its metabolites will be necessary to determine plasma concentrations that correlate with clinical effectiveness to determine the therapeutic range for the treatment of pituitary pars intermedia dysfunction.

AB - Objective: To determine the pharmacokinetics of pergolide after IV administration to horses. Animals: 8 healthy adult horses. Procedures: Pergolide mesylate was administered IV at a dose of 20 µg/kg (equivalent to 15.2 µg of pergolide/kg) to each horse, and blood samples were collected over 48 hours. Pergolide concentrations in plasma were determined by means of high-performance liquid chromatography'tandem mass spectrometry, and pharmacokinetic parameters were determined on the basis of noncompartmental methods. Results: After IV administration of pergolide, mean ± SD clearance, elimination halflife, and initial volume of distribution were 959 ± 492 mL/h/kg, 5.64 ± 2.36 hours, and 0.79 ± 0.32 L/kg, respectively. Conclusions and clinical relevance: With an elimination half-life of approximately 6 hours, twice-daily dosing may be more appropriate than once-daily dosing to reduce peak-trough fluctuation in pergolide concentrations. Further pharmacodynamic and pharmacokinetic studies of pergolide and its metabolites will be necessary to determine plasma concentrations that correlate with clinical effectiveness to determine the therapeutic range for the treatment of pituitary pars intermedia dysfunction.

KW - Corticotropin

KW - Pergolide

U2 - 10.2460/ajvr.76.2.155

DO - 10.2460/ajvr.76.2.155

M3 - Article

C2 - 25629913

VL - 76

SP - 155

EP - 160

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 2

ER -